Imatinib, an inhibitor targeting exons 9/11‐mutated KIT gene, is the first‐line therapy for advanced GIST, while most imatinib‐treated patients ultimately relapse, possibly due to the outgrowth of clones carrying KIT mutations associated with imatinib resistance, typically involve KIT exons 13/14 (ATP‐binding pocket) and 17/18 (activation loop).39, 40, 41. This evidence concerns the gene KIT and gastrointestinal stromal tumor.